ARP 1536 anti VEGF bispecific antibody - Whitehawk Therapeutics
Alternative Names: ARP 1536-AVLatest Information Update: 02 Apr 2025
At a glance
- Originator Aerpio Pharmaceuticals
- Developer Whitehawk Therapeutics
- Class Bispecific antibodies; Eye disorder therapies
- Mechanism of Action Receptor-like protein tyrosine phosphatase inhibitors; TIE-2 receptor agonists; Vascular endothelial growth factors inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diabetic macular oedema; Wet age-related macular degeneration
Most Recent Events
- 18 Mar 2025 Aadi Bioscience is now called Whitehawk Therapeutics
- 28 Nov 2023 No recent reports of development identified for preclinical development in Diabetic-macular-oedema in USA (Intravitreous, Injection)
- 28 Nov 2023 No recent reports of development identified for preclinical development in Wet age-related macular degeneration in USA (Intravitreous, Injection)